Cerenovus to invest €50m to expand Galway site

Stroke is the biggest cause of acquired disability and the third biggest cause of death in Ireland.

Emerging leader in neurovascular care Cerenovus is to invest €50m over the next three years at its Galway site.

Cerenovus Galway, part of the Johnson & Johnson group of medical device companies, is a world-leading research site for stroke and is at the forefront of developing a broad portfolio of innovative medical devices to treat this debilitating condition.

“Galway is now one of Europe’s premier medtech hubs with one of the highest concentrations of medical technology companies in Europe”

Ischemic stroke, caused by clots in vessels which block blood supplied to the brain, accounts for 87% of all strokes, reportedly affecting 1m patients every year in Europe. In Ireland, approximately 7,500 people have a stroke each year – one third of all strokes happen in people under sixty-five years of age.

Time is of the essence

Stroke is the biggest cause of acquired disability and the third biggest cause of death in Ireland.

“Stroke can be a devastating event for patients and their loved ones, and recovery depends on physicians having options to treat patients effectively and efficiently in the hours after their stroke,” explained Michael Gilvarry, general manager of Cerenovus Galway.

“Our work at Cerenovus is focused on providing devices that change the trajectory of stroke, to protect patients from stroke-related disabilities. At Cerenovus Galway, we develop devices using our unique capabilities simulating the underlying diseases that cause stroke. This is based on scientific research conducted under the umbrella of the Cerenovus Neuro Thromboembolic Initiative (NTI).

“We work closely with universities and academics, including strong collaborations locally with GMIT and NUI Galway,” Gilvarry said.

Welcoming the investment, Minister for Further and Higher Education, Research, Innovation and Science Simon Harris, TD, said: “This is a significant investment in Galway and a signal of Johnson & Johnson’s continued commitment to our growing research, development and Innovation system here.

“Here in Ireland, we have the tools and the talent to address the key challenges facing society and our people. Galway is now one of Europe’s premier medtech hubs with one of the highest concentrations of medical technology companies in Europe. New, innovative technologies and treatments like the ones that are being developed at Cerenovus will make it possible to deliver better clinical outcomes and improve the quality of life for patients.”

Main image at top (from left): Michael Gilvarry, general manager of Cerenovus, with Simon Harris, TD, Minister for Further and Higher Education, Research, Innovation and Science, and Dr Sarah Power, Interventional Neuroradiologist at Beaumont Hospital

John Kennedy
Award-winning ThinkBusiness.ie editor John Kennedy is one of Ireland's most experienced business and technology journalists.

Recommended